Ind-Swift Laboratories Ltd - 532305 - Board Meeting Intimation for Meeting To Be Held On August 10, 2026.
Ind Swift Laboratories board will convene on August 10, 2026, to review and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
Aug 03 2026 17:10:46
Ind-Swift Laboratories Ltd - 532305 - Corrigendum To The Notice Of 01/2026-27 Extra-Ordinary General Meeting ('EGM Notice') Dated July 10, 2026
Ind Swift Laboratories provided clarity on the utilization of Rs.137.20 crore to be raised through a preferential issue of fully convertible warrants. The funds are earmarked for business expansion, R&D, technology upgradation, investment in a subsidiary, and working capital.
Jul 29 2026 18:37:46
Ind-Swift Laboratories Ltd - 532305 - Outcome Of The Preferential Issue Committee Of The Board Of Directors Of Ind-Swift Laboratories Limited In Terms Of The Provisions Of Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Ind Swift Laboratories' Preferential Issue Committee met on July 29, 2026, and approved a corrigendum to the EGM notice. This EGM, scheduled for August 5, 2026, will seek shareholder approval for a proposed preferential issue of fully convertible warrants.
Jul 29 2026 17:45:26
Ind-Swift Laboratories Ltd - 532305 - Notice Of Extra-Ordinary General Meeting To Be Held On August 05, 2026
Ind Swift Laboratories' EGM notice explicitly discloses that the company and its promoters were declared "wilful defaulters" by Central Bank of India for an Rs.9.56 crore loan. Although the loan was fully repaid in 2020 and a court case is pending to remove the tag, the disclosure of this status is a significant governance flag for investors.
Jul 14 2026 19:44:29
Ind-Swift Laboratories Ltd - 532305 - Board Meeting Outcome for Outcome Of Meeting Of The Board Of Directors Of Ind-Swift Laboratories Limited ('The Company') In Terms Of The Provisions Of Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Ind Swift Laboratories board approved preferential issue of up to 70 lakh fully convertible warrants to Essix Biosciences Limited (Promoter & Promoter Group). The issue aggregates ₹137.20 crore at ₹196 per warrant. Warrants are convertible into equity shares within 18 months, subject to EGM approval on August 5, 2026.
Jul 10 2026 19:13:46
Ind-Swift Laboratories Ltd - 532305 - Board Meeting Intimation for Meeting To Be Held On `10/07/2026
Ind Swift Laboratories' Board of Directors will meet on July 10, 2026. The agenda includes considering a proposal to raise funds through various instruments, such as Preferential Issue, Rights Issue, or QIP.
Jul 07 2026 19:21:43
Read More